I support biotech and pharma sponsors who need experienced, independent oversight of clinical trial execution.
I am engaged on a part-time or project basis to assess CRO delivery models, identify early execution risk, and stabilize Phase I–III programs before timelines, quality, or budgets are compromised.
Typical engagements include:
CRO performance and governance assessments
Program execution risk reviews (timelines, enrollment, vendors, data quality)
Study start-up or mid-study remediation
Critical path recovery and milestone realignment
Inspection readiness and TMF stabilization
My background spans sponsor-side leadership, CRO delivery, and investigator experience across oncology, rare disease, cardiology, and imaging-intensive trials. I focus on early signals that predict downstream failure and provide clear, actionable recommendations for course correction.
Engagements are structured, time-bound, and outcome-focused.